From January 1, 2024 to March 31, 2024, the company has repurchased 2,966,000 shares, representing 0.2% for CNY 38.41 million. With this, the company has completed the repurchase of 7,023,100 shares, representing 0.48% for CNY 99.99 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.39 CNY | -0.34% | -1.25% | +18.54% |
May. 13 | Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution | MT |
May. 02 | Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.54% | 3.53B | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.